The historical rank and industry rank for Bicycle Therapeutics's Days Payable or its related term are showing as below:
FRA:50BA's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.36 * Ranked among companies with meaningful Days Payable only.
Bicycle Therapeutics's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Bicycle Therapeutics Days Payable Related Terms
Bicycle Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Bicycle Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:50BA vs IFRX, ELDN, ZNTL: Days Payable Comparison
For the Biotechnology subindustry, Bicycle Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bicycle Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Bicycle Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bicycle Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bicycle Therapeutics (FRA:50BA) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bicycle Therapeutics and its competitors. According to the industry distribution chart, Bicycle Therapeutics ranks #999999 out of 705 companies in the Biotechnology industry.
Is Bicycle Therapeutics' Days Payable too high?
Bicycle Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Bicycle Therapeutics ranks #999999 out of 705 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bicycle Therapeutics has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bicycle Therapeutics' Days Payable compare to IFRX and ELDN?
According to the Biotechnology industry distribution chart, Bicycle Therapeutics ranks #999999 out of 705 companies for Days Payable. This places Bicycle Therapeutics in the lower half of its industry. The industry median Days Payable is 113.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bicycle Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bicycle Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicycle Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bicycle Therapeutics (FRA:50BA) is currently considered Possible Value Trap. The stock's GF Value™ is €12.81, compared to a current price of €3.52 — trading 72.5% below its estimated fair value. The current Days Payable is 0.00. Bicycle Therapeutics' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bicycle Therapeutics (FRA:50BA), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bicycle Therapeutics (FRA:50BA) Overvalued in 2026?
Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued.
The current stock price of €3.52 is trading 72.5% below its estimated GF Value™ of €12.81.
GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.
Key valuation signals for FRA:50BA:
Days Payable: 0.00
GF Value™: €12.81 vs. price of €3.52 (72.5% below fair value)
No single metric tells the full story. See the FRA:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
56GF Score
Get the complete analysis for FRA:50BA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:50BA has been successfully added to your 
